Please provide your email address to receive an email when new articles are posted on . GenePOC Inc. has announced the launch and FDA clearance of its Clostridium difficile molecular test, GenePOC ...
Great Basin Corporation Submits 510(K) Application to FDA for C. Difficile Molecular Diagnostic Test
SALT LAKE CITY--(BUSINESS WIRE)-- Great Basin Corporation, a privately held life sciences company developing sample-to-result molecular diagnostic solutions, today announced it has submitted a 510(k) ...
Many clinical practice guidelines for preventing Clostridium difficile infections do not comply with the reporting standards outlined in the Appraisal of Guidelines for Research and Evaluation II ...
56% Increase in C. diff Due in Part to Improved Detection Hospitals that switched Clostridium difficile testing from nonmolecular to molecular methods recorded a 56 percent increase in recorded C.
Arlington, Va. — June 27, 2024 — A new study published today in the American Journal of Infection Control (AJIC) describes the outcome of a new approach to testing for Clostridioides difficile (C.
Clostridium difficile infection is one of the most common healthcare-associated infections in adults in the United States. Older Americans are especially vulnerable to CDI, 2 and this infection has ...
Recurrent C. diff infection is when you contract a C. diff infection 2 to 8 weeks after completing treatment for a previous one. C. diff relapse is a recurrence of the same strain, while reinfection ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback